Cabergoline versus Raloxifen effect in acromegaly.

Cabergoline versus Raloxifen in active acromegaly: A block randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016041025917N2

Enrollment

Registered

2016-09-14

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly. Acromegaly and pituitary gigantism

Interventions

Intervention 1: Patients in the first group receive cabergoline 1 mg 3 times weekly for 3 months. Intervention 2: The second intervention group receive raloxifen 60 mg 2 times daily for 3 months.

Treatment - Drugs

Patients in the first group receive cabergoline 1 mg 3 times weekly for 3 months.

The second intervention group receive raloxifen 60 mg 2 times daily for 3 months.

Eligibility

Sex/Gender

All

Age

18 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age older than 18 years; high IGF-1 for age and sex; being on treatment with Sandostatin-LAR (post pituitary surgery) every 28 days for a minimum duration of 3 months. Exclusion criteria: malignancy; advanced hepatic and renal insufficiency.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IGF-1. Timepoint: Before and 3 months after trial onset. Method of measurement: Laboratory measurement.;Blood pressure. Timepoint: 0,3 months. Method of measurement: Blood pressure monitor.;FBS. Timepoint: 0,3 months. Method of measurement: Laboratory.;BUN. Timepoint: 0,3 months. Method of measurement: Laboratory.;Cr. Timepoint: 0,3 months. Method of measurement: Laboratory.;GH. Timepoint: 0,3 months. Method of measurement: Laboratory(RIA).;BMI. Timepoint: 0,3 months. Method of measurement: Calculation.	—

Measure

Time frame

IGF-1. Timepoint: Before and 3 months after trial onset. Method of measurement: Laboratory measurement.;Blood pressure. Timepoint: 0,3 months. Method of measurement: Blood pressure monitor.;FBS. Timepoint: 0,3 months. Method of measurement: Laboratory.;BUN. Timepoint: 0,3 months. Method of measurement: Laboratory.;Cr. Timepoint: 0,3 months. Method of measurement: Laboratory.;GH. Timepoint: 0,3 months. Method of measurement: Laboratory(RIA).;BMI. Timepoint: 0,3 months. Method of measurement: Calculation.

—

Secondary

Measure	Time frame
IGF1. Timepoint: Before and 3 months after trial onset. Method of measurement: Laboratory measurement-.;BMI. Timepoint: 0,3 months. Method of measurement: Calculation.;Blood pressure. Timepoint: 0,3 months. Method of measurement: Blood pressure monitor.;GH. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.;FBS. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.;BUN. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.;Cr. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.	—

Measure

Time frame

IGF1. Timepoint: Before and 3 months after trial onset. Method of measurement: Laboratory measurement-.;BMI. Timepoint: 0,3 months. Method of measurement: Calculation.;Blood pressure. Timepoint: 0,3 months. Method of measurement: Blood pressure monitor.;GH. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.;FBS. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.;BUN. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.;Cr. Timepoint: 0,3 months. Method of measurement: Laboratory measurement-.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPoopak Asadi, MD

The Institute of Endocrinology, Iran University of Medical Sciences

pipakasadi@yahoo.com+98 21 8894 5247

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026